This Biotech Stock Has Soared 175%. Here’s Why One Fund Still Sold $3 Million Worth

57 minutes ago 3

Jonathan Ponciano, The Motley Fool

Sat, May 9, 2026 astatine 11:13 AM CDT 4 min read

On May 8, 2026, JW Asset Management reported selling 83,600 shares of Liquidia Corporation (NASDAQ:LQDA), an estimated $3.10 cardinal commercialized based connected quarterly mean pricing.

What happened

According to an SEC filing dated May 8, 2026, JW Asset Management reduced its holdings successful Liquidia by 83,600 shares. The estimated transaction value, calculated utilizing the mean closing terms for the archetypal 4th of 2026, was $3.10 million. After the trade, the money reported holding 16,176 shares worthy $610,482 astatine quarter-end. The nett presumption worth decreased by $2.83 cardinal implicit the period.

What other to cognize

This was a sale, reducing the involvement to 0.25% of JW Asset Management's $243.51 cardinal successful reportable U.S. equity assets.
Top holdings aft the filing:
- NASDAQ: ESTA: $173.84 cardinal (71.4% of AUM)
- NASDAQ: COCO: $10.47 cardinal (4.3% of AUM)
- NASDAQ: CPRX: $9.62 cardinal (3.9% of AUM)
- NASDAQ: GOOGL: $7.90 cardinal (3.2% of AUM)
- NASDAQ: IREN: $5.64 cardinal (2.3% of AUM)
As of May 7, 2026, Liquidia shares were priced astatine $42.28, up 175% implicit the past twelvemonth and vastly outperforming the S&P 500 by astir 145 percent points.
The presumption was antecedently 1.1% of the fund's AUM arsenic of the anterior quarter.

Company Overview

Metric

Value

Market Capitalization	$3.73 billion
Revenue (TTM)	$158.32 million
Net Income (TTM)	$-68.92 million

Company Snapshot

Liquidia develops and commercializes biopharmaceutical products, including YUTREPIA (inhaled adust pulverization treprostinil) and distributes generic treprostinil injection successful the United States.
The institution generates gross done the merchantability of proprietary and generic therapies targeting pulmonary arterial hypertension and related conditions.
It serves healthcare providers and patients with unmet aesculapian needs successful the U.S. uncommon illness and pulmonary hypertension markets.

Liquidia Corporation is simply a biotechnology institution focused connected processing and commercializing therapies for pulmonary arterial hypertension and different uncommon diseases. The institution leverages proprietary cause transportation exertion to code important unmet needs successful the U.S. healthcare market.

What this transaction means for investors

This merchantability yet looks much similar profit-taking aft an explosive tally than a implicit nonaccomplishment of assurance successful Liquidia’s commercialized story, peculiarly since JW Asset Management kept a smaller involvement adjacent arsenic shares skyrocketed astir 175% implicit the past twelvemonth and dramatically outpaced the broader market.

The bigger communicative for semipermanent investors is that Liquidia is nary longer conscionable a development-stage biotech promising aboriginal potential. YUTREPIA, the firm’s inhaled medicine utilized to dainty precocious humor unit successful the lungs, generated $148.3 cardinal successful nett merchandise income during 2025, including $90.1 cardinal successful the 4th fourth alone, portion the institution posted its 2nd consecutive profitable quarter. Liquidia besides ended the twelvemonth with $190.7 cardinal successful cash, up much than $33 cardinal from the anterior quarter.

The institution said it has received much than 3,600 prescriptions and treated implicit 2,900 patients since launch. The adjacent important catalyst is coming connected Monday, erstwhile the steadfast is acceptable to study first-quarter earnings.

Read Entire Article